BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21514251)

  • 1. Diffuse alveolar hemorrhage as a complication of dual antiplatelet therapy for acute coronary syndrome.
    Ikeda M; Tanaka H; Sadamatsu K
    Cardiovasc Revasc Med; 2011; 12(6):407-11. PubMed ID: 21514251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?
    Nguyen MC; Lim YL; Walton A; Lefkovits J; Agnelli G; Goodman SG; Budaj A; Gulba DC; Allegrone J; Brieger D;
    Eur Heart J; 2007 Jul; 28(14):1717-22. PubMed ID: 17562671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
    Persson J; Lindbäck J; Hofman-Bang C; Lagerqvist B; Stenestrand U; Samnegard A
    EuroIntervention; 2011 Apr; 6(9):1046-52, 8-9. PubMed ID: 21518675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    ; Mehta SR; Bassand JP; Chrolavicius S; Diaz R; Eikelboom JW; Fox KA; Granger CB; Jolly S; Joyner CD; Rupprecht HJ; Widimsky P; Afzal R; Pogue J; Yusuf S
    N Engl J Med; 2010 Sep; 363(10):930-42. PubMed ID: 20818903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
    Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
    Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
    Jeong YH; Park Y; Kim IS; Yun SE; Kang MK; Hwang SJ; Kwak CH; Hwang JY
    Thromb Haemost; 2010 Dec; 104(6):1286-9. PubMed ID: 20838742
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
    Orford JL; Fasseas P; Melby S; Burger K; Steinhubl SR; Holmes DR; Berger PB
    Am Heart J; 2004 Mar; 147(3):463-7. PubMed ID: 14999195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
    Rubboli A; Halperin JL
    Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
    Khurram Z; Chou E; Minutello R; Bergman G; Parikh M; Naidu S; Wong SC; Hong MK
    J Invasive Cardiol; 2006 Apr; 18(4):162-4. PubMed ID: 16729401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
    Roldán V; Marín F
    Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.
    Pollack CV; Hollander JE
    J Emerg Med; 2008 Jul; 35(1):5-13. PubMed ID: 18359601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
    Chhatriwalla AK; Bhatt DL
    Circ Cardiovasc Interv; 2008 Dec; 1(3):217-25. PubMed ID: 20031681
    [No Abstract]   [Full Text] [Related]  

  • 18. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study.
    Cayla G; Silvain J; Barthelemy O; Connor S'; Payot L; Bellemain-Appaix A; Beygui F; Aout M; Collet JP; Vicaut E; Montalescot G;
    Heart; 2011 Jun; 97(11):887-91. PubMed ID: 21421600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial.
    Collet JP; Montalescot G; Steg PG; Steinhubl SR; Fox KA; Hu TF; Johnston SC; Hamm CW; Bhatt DL; Topol EJ
    Arch Cardiovasc Dis; 2009; 102(6-7):485-96. PubMed ID: 19664568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.